Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

>

$
4,212$
76,820LIABILITIES AND STOCKHOLDERS' EQUITY   Deferred revenue

$
2,368$
,099   Other current liabilities

4,4833,910Total current liabilities

6,85110,009   Deferred rent

3650Total liabilities

6,88710,059Stockholders' equity

57,32566,761Total liabilities and stockholders' equity

$
4,212$
76,820* Marketable securities

$
43,771$
22,950Pharmacyclics, Inc.(a development stage enterprise)

Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data)Three Months EndedDecember 31,Six Months Ended December 31,2010200920102009Revenues:   License and milestone revenues

$
2,824$
4,702$
4,788$
4,702Total revenues

2,8244,7024,7884,702Operating expenses:   Research and development

8,2563,72315,9587,011   General and administrative

2,0931,7653,9273,298Total operating expenses

10,3495,48819,88510,309Loss from operations

(7,525)(786)(15,097)(5,607)Interest and other income (expense), net

261875(6)Loss before provision for income tax

(7,499)(768)(15,022)(5,613)Benefit from income tax

-550-550Net loss

$
(7,499)$
(218)$  (15,022)$   (5,063)Basic and diluted net loss per share

$
(0.13)$
(0.00)$
(0.25)$   (0.11)Shares used to compute basic and   diluted net loss per share

59,71550,07659,49745,535Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)(unaudited; in thousands, except per share data)Three Months EndedDecember 31,20102009GAAP net loss$
(7,499)$
(218)Adjustments:Research & development share-based compensation(2)

1,267216General & administrative share-based compensation(2)

671356Income tax adjustment(3)

-(550)Therapeutic discovery project tax grant, net(4)

(586)-1,35222License and collaboration revenues(5)

-(1,211)-(1,211)Non-
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
3. Pharmacyclics, Inc. Rights Offering Oversubscribed
4. Pharmacyclics Announces Subscription Price for Rights Offering
5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
9. Pharmacyclics Secures $5.0 Million in Debt Financing
10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015 Proove Biosciences , a ... presented two scientific posters at the Annual Clinical Genetics ... four-day event was hosted at the Salt Palace Convention ... educating genetic and genomic professionals on breakthrough advances in ... Study on the Role of DAT1 in Risk of ...
(Date:4/1/2015)... , April 1, 2015  Among 1,050 U.S. ... about oral cancer (68 percent) and only 36 percent ... dental check-up, according to findings from a survey ... a leading innovator and developer of solutions that aid ... The online survey polled 1,050 U.S. consumers on ...
(Date:4/1/2015)... DIEGO , April 1, 2015  Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... three-dimensional kidney tissue at the 2015 Experimental Biology ... "Kidney represents an ideal extension ... that can be tremendously useful in pharmaceutical research," ...
(Date:4/1/2015)... YORK , April 1, 2015 ... advancing protein biologic therapies and oncology supportive care ... 2014 achievements and a strategic update for 2015. ... Company has made in the areas of business ... programs, the FDA clearance of the ProctiGard product, ...
Breaking Biology Technology:Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6
... Israel, December 2 InSightec Ltd. announced,today that ... with the ExAblate(R) system has the potential to ... have spread to,the bones (bone metastases). The results ... 11 online issue of Annals of Surgical Oncology, ...
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... BASKING RIDGE, N.J., Dec. 2 Regado Biosciences, Inc., ... newly created position of Senior Vice President of Business ... McDonald brings to Regado nearly 20 years of experience ... operations, portfolio management and marketing. She will report ...
Cached Biology Technology:New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
... to humans, the bacteria and tiny plants living in the ... is quite different than ours for one, they can,t ... red meat for a pick-me-up. So where does their ... " points to a source on the seafloor: minute particles ...
... a specific sugar residue on the cell surface, which is ... Faissner has now been able to use LewisX for the ... researchers report on their results in the Journal of ... Antibodies that recognise the LewisX sugar residue are used routinely ...
Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2As good as gold 2
Taq DNA polymerase, 10,000U...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
... Reduce bench time to just 15 minutes! ... paralles that can be drawn between this exciting ... of instant foods. Instant meals consumed by ... format and are reconstituted by adding water. ...
Biology Products: